Generated July 6, 2026 at 8:31 PM ET
· Covers July 6 trading day
· 7 of 188 ready 8-Ks selected
· AI-assisted overview
Today's filings highlight major corporate actions: Vertex agreed to acquire Crinetics for $85/share (~$10B equity value), adding PALSONIFY and atumelnant. Incyte completed its $1.25B acquisition of Vega Therapeutics, gaining Phase 3 VWD asset VGA039. CoreCivic sold two detention facilities to DHS for $1.5B, netting ~$1.1B after taxes. TXNM Energy received a final NMPRC order voiding its $400M PIPE investment, imposing a $300K penalty and requiring unwinding. Invivyd received FDA notice of PEMGARDA EUA termination effective June 29, 2027, and plans to pursue BLA approval. Polar Power received a Nasdaq extension to October 28, 2026 to regain stockholders' equity compliance. Tutor Perini issued $400M 6.625% notes due 2033, redeemed higher-cost notes, and amended its credit facility to increase revolver capacity and reduce margins.
regulatory
negative
materiality 0.85
July 6, 2026, 7:28 AM ET
NMPRC voids $400M PIPE investment in TXNM merger, orders unwinding and $300K penalty
- NMPRC final order declares PIPE Transaction void for lack of prior approval under New Mexico Public Utility Act.
- TXNM, Parent, and Purchaser each fined $100,000 (aggregate $300,000).
- Compliance report required within 45 days detailing unwinding of PIPE Transaction and ratepayer protections.
CRNX
Crinetics Pharmaceuticals, Inc.
M&A
positive
materiality 0.90
July 6, 2026, 5:17 PM ET
Vertex to acquire Crinetics for $85/share, ~$10B equity value, adding PALSONIFY and atumelnant
- Vertex to acquire Crinetics for $85.00 per share in cash, total equity value ~$10.0B (~$8.8B net of cash).
- Crinetics' PALSONIFY (once-daily oral for acromegaly) launched in 2025; atumelnant (ACTH receptor antagonist) in Phase 3 for CAH.
- Transaction unanimously approved by both boards; expected to close in Q3 2026, subject to stockholder and regulatory approvals.
regulatory
negative
materiality 0.85
July 6, 2026, 7:11 AM ET
Invivyd receives FDA notice of PEMGARDA EUA termination effective June 29, 2027; plans to pursue BLA approval
- FDA sent Invivyd Notice of Termination for PEMGARDA EUA, effective June 29, 2027, following HHS termination of COVID-19 EUA declaration.
- PEMGARDA (pemivibart) authorized since March 2024 for COVID-19 pre-exposure prophylaxis in immunocompromised individuals.
- Invivyd intends to pursue Biologics License Application (BLA) for full FDA approval, citing clinical and post-authorization data.
M&A
positive
materiality 0.85
July 6, 2026, 4:06 PM ET
Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039
- Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).
- Upfront payment of $1.25B; up to $750M in additional sales milestones for Star Therapeutics.
- VGA039 has Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease FDA designations.
M&A
positive
materiality 0.85
July 6, 2026, 8:00 AM ET
CoreCivic sells two detention facilities to DHS for $1.5B; net proceeds ~$1.1B
- Sold California City (2,560 beds) for $732.6M and Otay Mesa (1,994 beds) for $739.2M to DHS.
- Net proceeds after ~$0.4B taxes and expenses expected to be ~$1.1B.
- Proceeds to repay $477.8M bank credit facility and $238.5M of 4.75% senior notes due 2027.
regulatory
negative
materiality 0.75
July 6, 2026, 5:25 PM ET
Polar Power gets Nasdaq extension to Oct 28, 2026 to regain stockholders' equity compliance
- Stockholders' equity was only $144,000 as of Dec 31, 2025, triggering Nasdaq Rule 5550(b) deficiency.
- Company submitted a compliance plan on June 15, 2026; Nasdaq granted extension on June 29, 2026.
- Deadline to evidence compliance is October 28, 2026, via one of two specified public disclosure alternatives.
debt
positive
materiality 0.80
July 6, 2026, 9:03 AM ET
Tutor Perini issues $400M 6.625% notes due 2033, redeems 11.875% 2029 notes, amends credit facility
- Issued $400M 6.625% notes due 2033; proceeds used to redeem $400M 11.875% 2029 notes at 108.906%.
- Amended credit agreement: revolver increased from $170M to $350M, maturity extended to July 2, 2031.
- SOFR margin reduced to 1.75%-2.50% (from 4.25%-4.75%); base rate margin reduced to 0.75%-1.50%.